Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Clin Cancer Res. 2021 Aug 18;27(21):5961–5978. doi: 10.1158/1078-0432.CCR-21-0986

Table 1.

Best objective response

Best Objective Response TKI naïve Viral HCC N=15 TKI naïve Non-viral HCC N=11 TKI experienced Viral HCC N=6 TKI experienced Non-viral HCC N=4
Total evaluable (%) 15 (100) 11 (100) 6 (100) 4 (100)
Objective Response (%) 4 (26.7) 1 (9.1) 0 0
- Complete Response 2 ( 13.3) 0 0 0
- Partial Response 2 (13.3) 1 ( 9.1) 0 0
Stable Disease (%) 7 (46.7) 7 ( 63.6) 6 (100) 4 (100)
Progressive Disease (%) 4 (26.7) 3 (27.3) 0 0